| |
Effective |
Permeability |
Coefficient |
X 10-4 |
cm/min |
|
|
|
|
| Compound |
Frogd |
humana |
Ratb |
CACO-2c |
PAMPAc |
BCSa |
Frogd |
Humana
FA % |
Kax10-4/min |
| Metaprolol |
0.3 ± 0.052 |
1.3 ± 10-4 |
0.20 ± 0.04 |
0.23 |
0.035 |
H |
H |
96 |
1.2 |
| Naproxen |
1.865 ± 0.17 |
8.3 ± 4.8 |
1.19 ± 0.12 |
0.39 |
0.106 |
H |
H |
100 |
7.2 |
| Ranitidine |
0.094 ± 0.07 |
0.27 ± 0.06 |
0.073 ± 0.06 |
0.004 |
0.005 |
L |
L |
50 |
0.37 |
| Cimetidine |
0.129 ± 0.06 |
0.3 ± 0.05 |
0.105 ± 0.06 |
0.007 |
0.0 |
L |
L |
60 |
0.516 |
| Ketoprofen |
2.22 ± 0.23 |
8.4 ± 3.3 |
1.55 ± 0.34 |
- |
0.167 |
H |
H |
100 |
8.88 |
| Hydrochlorthiazide |
0.013 ± 0.002 |
0.04 ± 0.05 |
0.001 ± 0.001 |
0.005 |
0.0 |
L |
L |
67 |
0.052 |
| Verapamil |
1.186 ± 0.08 |
6.7 ± 2.9 |
0.65 ± 0.05 |
0.117 |
0.074 |
H |
H |
100 |
4.74 |
| Atenolol |
0.083 ± 0.05 |
0.2 ± 0.2 |
0.060 ± 0.06 |
0.002 |
0.0 |
L |
L |
50 |
0.332 |
| Antipyrine |
1.325 ± 0.12 |
4.5 ± 2.5 |
0.96 ± 0.13 |
0.28 |
0.132 |
H |
H |
100 |
5.3 |
| Fluvastatin |
0.827 ± 0.07 |
2.4 ± 1.8 |
0.50.04 |
-- |
- |
H |
H |
98 |
3.3 |
| Furosemide |
0.0124 ± 0.03 |
0.04 ± 0.04 |
0.117 ± 0.08 |
0.001 |
0.006 |
L |
L |
61 |
0.05 |
| Ciprofloxacin |
0.2 ± 0.85 |
- |
0.155 ± 1.98 |
0.028 |
0.0017 |
L |
L |
- |
0.8 |
a. Winiwarter et al., [30]; Takamatsu et al.,1997; Takamatsu et al.,[29]; Lennernas et al [26]; Lennernas et al,1995;
b. Fagerholm et al.,[24]; Kim et al., [21].
c. Zhu et al.,[31]; Bermajo et al.,2003.
Determined in this study |
